Pfizer’s Berobenatide GLP‑1 Receptor Agonist Shows Mid‑Stage VESPER‑3 Trial Results

Pfizer’s investigational drug Berobenatide, a GLP-1 receptor agonist, shows promising mid-stage trial results in the VESPER-3 trial. The news relates to an experimental, ultra-long-acting peptide for chronic weight management and type 2 diabetes. It is discussed as a potential monthly injection option for obesity treatment.

Berobenatide (GLP‑1 Receptor Agonist):

Dimension	Key Details
Developer	Berobenatide is developed by Pfizer.
Drug class	Berobenatide comprises an experimental, ultra-long-acting glucagon-like peptide-1 receptor agonist (GLP-1 RA) peptide.
Indications	Berobenatide applies to chronic weight management and type 2 diabetes.
Current trigger	Berobenatide has shown promising mid-stage trial results in the VESPER-3 trial.
Mechanism (GLP‑1 action)	It mimics natural gut hormones that controls appetite, slows stomach emptying, and improves blood sugar.
Molecular structure	It comprises a unique structure that binds to a blood protein called albumin, which stops the body from breaking it down quickly and keeps the drug active longer.
Albumin fact	Albumin is the most abundant protein in human blood plasma, making up about 50% to 60% of total blood protein.
Dosage volume	It works in a 0.5 mL injection dose.
Duration of effect	It sustains therapeutic effect for an entire month with one shot.
Side-effect profile	It comprises nausea and vomiting as side effects.
Obesity definition	Obesity is governed by excess accumulation of body fat with BMI ≥ 30.
Drivers of obesity	Obesity is driven by genetic, socioeconomic, and lifestyle factors.
Health risks associated with obesity	Health risks comprise cardiovascular disease, Type 2 diabetes, hypertension, dyslipidemia, liver disease, sleep apnea, and cancers.